Prospective Screening for Human Leukocyte Antigen-B*5701 Avoids Abacavir Hypersensitivity Reaction in the Ethnically Mixed French HIV Population

Mallal, 2002, Association between presence of HLA-B*5701, HLA5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir., Lancet, 359, 727, 10.1016/S0140-6736(02)07873-X

Martin, 2004, Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a h5701 and a haplotypic Hsp70-Hom variant., Proc Natl Acad Sci USA, 101, 4180, 10.1073/pnas.0307067101

Rauch, 2006, Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study., Clin Infect Dis, 43, 99, 10.1086/504874

Hetherington, 2002, Genetic variations in HLA-B region and hypersensitivity reactions to abacavir., Lancet, 359, 1121, 10.1016/S0140-6736(02)08158-8

Hughes, 2004, Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations., Pharmacogenomics, 5, 203, 10.1517/phgs.5.2.203.27481

Phillips, 2005, Clinical and immunogenetic correlates of abacavir hypersensitivity., AIDS, 19, 979, 10.1097/01.aids.0000171414.99409.fb

Phillips, 2006, Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?, Clin Infect Dis, 43, 103, 10.1086/504878

Martin, 2005, HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing., Tissue Antigens, 65, 571, 10.1111/j.1399-0039.2005.00401.x